PaperFirst line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma
References (13)
- et al.
The concentration of radioactivity for labelled epinephrine and its precursors in the dog adrenal medulla
J Nucl Med
(1967) - et al.
Scintigraphic localization of pheochromocytoma
New Engl J Med
(1981) - et al.
Iodine-131 metaiodobenzylguanidine for the location of suspected pheochromocytoma: experience in 400 cases
J NuclMed
(1985) - et al.
Radiopharmaceutical treatment of malignant pheochromocytoma
J Nucl Med
(1984) - et al.
Radionuclide diagnosis and treatment of neural crest tumors using iodine-131-meta-iodobenzylguanidine
J Nucl Med
(1987) - et al.
Mechanisms of uptake of norepinephrine (NE) and meta-iodobenzylguanidine (MIBG) into cultured human pheochromocytoma cells
J Nucl Med
(1984)
Cited by (71)
Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects
2018, Medecine Nucleaire<sup>131</sup>I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications
2016, Seminars in Nuclear MedicineCitation Excerpt :Overall response rate in this trial was 25%; myelosuppression and diarrhea were the most common toxicities. Although historically 131I-mIBG was used for treatment of those with relapsed or refractory disease, single center, small pilot studies suggest avidity when given at the time of diagnosis or in conjunction with induction chemotherapy; in other words, when used as a “front-line treatment.”92,93 According to De Kraker et al,52 the aim of using radionuclide therapy as a first-line treatment is threefold: to reduce the volume of the primary tumor and the number of malignant cells at metastatic sites thus enabling adequate surgical resection, to avoid the toxicity associated with chemotherapy, as well as to reduce the early induction of drug resistance.
A systematic review of <sup>131</sup>I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
2014, European Journal of CancerRadiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
2008, Nuclear Medicine and BiologyIodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age
2008, European Journal of CancerCitation Excerpt :From April 1989 to October 1999, 44 consecutive children diagnosed with high-risk, MIBG positive neuroblastoma were included in the study. Thirty three of these 44 children were included in a preliminary report.9 On-study characteristics are listed in Table 1.